1. Late effects in pediatric Hodgkin lymphoma survivors after uniform treatment with ABVD with or without radiotherapy
- Author
-
Chetan Patel, Sainath Bhethanabhotla, Abhenil Mittal, Sameer Bakhshi, Rajesh Khadgawat, Ahitagni Biswas, Shuvadeep Ganguly, Anant Mohan, and Sreenivas Vishnubhatla
- Subjects
Spirometry ,medicine.medical_specialty ,Adolescent ,Dacarbazine ,Vinblastine ,Gastroenterology ,Ventricular Function, Left ,Bleomycin ,Cancer Survivors ,DLCO ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Child ,Neoplasm Staging ,medicine.diagnostic_test ,business.industry ,Cumulative dose ,Stroke Volume ,Hematology ,Hodgkin Disease ,Regimen ,Oncology ,ABVD ,Doxorubicin ,Pediatrics, Perinatology and Child Health ,Thyroid function ,business ,medicine.drug - Abstract
PURPOSE ABVD (doxorubicin, bleomycin,vinblastine, and dacarbazine) is not a standard regimen in children due to concerns regarding late effects. However, no studies have evaluated long-term toxicities of ABVD in children. METHODS Total 154 pediatric Hodgkin lymphoma (HL) survivors uniformly treated with ABVD were clinically followed up as per institutional protocol. All participants were evaluated for cardiac, pulmonary, and thyroid function abnormalities by multigated acquisition scan (MUGA) scan, spirometry with diffusion capacity of lung for the uptake of carbon monoxide (DLCO), and thyroid profile test, respectively, at a single time point. Predictors of toxicity were also analyzed. RESULTS The median duration of follow-up of the cohort was 10.3 years (6.04-16.8). No secondary malignant neoplasm (SMN) or symptomatic cardiac/pulmonary toxicities were detected. Nine patients (5.9%) had left ventricular ejection fraction (LVEF)
- Published
- 2021